This site is intended for US healthcare professionals only.

BETHKIS LOGO

Email a colleague

Home/Request More Information

Request more information about BETHKIS®
(Tobramycin Inhalation Solution)

If you would like to learn more about BETHKIS, get updates when they become available, or to have one of our sales representatives contact you, please fill out the fields below.

All fields are required unless otherwise noted.

I'm interested in:

Additional information about BETHKIS as it becomes available.

Communication from a Chiesi sales representative.

Occupation

Title

First Name

Last Name

Email address

By checking the box below, you are giving Chiesi USA, Inc. permission to send you information and updates on BETHKIS or other treatment-related information in the future. Chiesi USA, Inc. will not sell or share any of your information with third parties.

I agree

I'm interested in:

Additional information about BETHKIS as it becomes available.

Communication from a Chiesi sales representative.

Occupation

Title

First Name

Last Name

Email address

Address Line 1

Address Line 2 (optional)

City

State

ZIP Code

Phone number

By checking the box below, you are giving Chiesi USA, Inc. permission to send you information and updates on BETHKIS or other treatment-related information in the future. Chiesi USA, Inc. will not sell or share any of your information with third parties.

I agree

Indication

BETHKIS® (Tobramycin Inhalation Solution) is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa. Safety and efficacy have not been demonstrated in patients under the age of six years, patients with FEV1 less than 40% or greater than 80% predicted, or patients colonized with Burkholderia cepacia.

Important Safety Information

BETHKIS is contraindicated in patients with a known hypersensitivity to any aminoglycoside.

Bronchospasm can occur with inhalation of BETHKIS. Bronchospasm and wheezing should be treated as medically appropriate.

Caution should be exercised when prescribing BETHKIS to patients with known or suspected auditory, vestibular, renal, or neuromuscular dysfunction. Audiograms, serum concentration, and renal function should be monitored as appropriate.

Avoid concurrent and/or sequential use of BETHKIS with other drugs with neurotoxic or ototoxic potential.

BETHKIS should not be administered concurrently with ethacrynic acid, furosemide, urea, or mannitol.

Aminoglycosides may aggravate muscle weakness because of a potential curare-like effect on neuromuscular function.

Fetal harm can occur when aminoglycosides are administered to a pregnant woman. Apprise women of the potential hazard to the fetus.

Common adverse reactions (more than 5%) occurring more frequently in BETHKIS patients are forced expiratory volume decreased, rales, red blood cell sedimentation rate increased, and dysphonia.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

 

Please see full prescribing information.

 

This website is intended for United States residents only.

Are you a patient, caregiver, or healthcare professional?

I AM A PATIENT/CAREGIVER

- or -

I AM A HEALTHCARE PROFESSIONAL